TY - JOUR
T1 - CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection
AU - Wei, Jing
AU - Peng, Jing
AU - Wang, Bing
AU - Qu, Hong
AU - Wang, Shiyi
AU - Faisal, Aziz
AU - Cheng, Jia Wei
AU - Gordon, John R.
AU - Li, Fang
PY - 2013
Y1 - 2013
N2 - Klebsiella pneumoniae-associated pathology is largely mediated by neutrophilic inflammation. In this study, we administered Klebsiella pneumoniae to experimental guinea pig groups and the ELR-CXC chemokine antagonist CXCL8 3 - 72, ceftazidime, and dexamethasone to different groups, respectively. After 24 h, we assessed the animal's pulmonary inflammatory levels, including gross histopathology, airway neutrophilia, lung myeloperoxidase levels, expressions of CXCL8 and TNF, and airway bacterial loads. Compared with ceftazidime and dexamethasone treatments, the administration of the ELR-CXC chemokine antagonist CXCL8 3 - 72 alone was more effective than other methods, although it did not markedly attenuate the bacterial load. These results suggest new methods for the treatment of Klebsiella pneumoniae pathology.
AB - Klebsiella pneumoniae-associated pathology is largely mediated by neutrophilic inflammation. In this study, we administered Klebsiella pneumoniae to experimental guinea pig groups and the ELR-CXC chemokine antagonist CXCL8 3 - 72, ceftazidime, and dexamethasone to different groups, respectively. After 24 h, we assessed the animal's pulmonary inflammatory levels, including gross histopathology, airway neutrophilia, lung myeloperoxidase levels, expressions of CXCL8 and TNF, and airway bacterial loads. Compared with ceftazidime and dexamethasone treatments, the administration of the ELR-CXC chemokine antagonist CXCL8 3 - 72 alone was more effective than other methods, although it did not markedly attenuate the bacterial load. These results suggest new methods for the treatment of Klebsiella pneumoniae pathology.
UR - http://www.scopus.com/inward/record.url?scp=84876577683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876577683&partnerID=8YFLogxK
U2 - 10.1155/2013/720975
DO - 10.1155/2013/720975
M3 - Article
C2 - 23586055
AN - SCOPUS:84876577683
VL - 2013
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 720975
ER -